The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluating maintenance therapies in advanced oesophago-gastric adenocarcinoma (OGA): Interim analysis and biomarker results from the PLATFORM study.
 
David Cunningham
Research Funding - 4SC (Inst); 4SC (Inst); 4SC (Inst); 4SC (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merrimack (Inst); Merrimack (Inst); Merrimack (Inst); Merrimack (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst)
 
Caroline Yean Kit Fong
No Relationships to Disclose
 
Clare Peckitt
No Relationships to Disclose
 
Gayathri Anandappa
No Relationships to Disclose
 
Michael Davidson
No Relationships to Disclose
 
Bijal Patel
No Relationships to Disclose
 
Andrea Turner
No Relationships to Disclose
 
Ruwaida Begum
No Relationships to Disclose
 
Catherine Cafferkey
No Relationships to Disclose
 
Katharina von Loga
No Relationships to Disclose
 
Marlon Rebelatto
Stock and Other Ownership Interests - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca
 
Russell D. Petty
Honoraria - Bristol-Myers Squibb; Lilly; Pfizer; Sanofi; SERVIER
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly; Pfizer; Sanofi; SERVIER
Speakers' Bureau - Bristol-Myers Squibb; Pfizer; Sanofi
Research Funding - AstraZeneca; Boston Biomedical; Clovis Oncology; Five Prime Therapeutics; Janssen; Lilly; Merck Serono; MSD; Roche
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Five Prime Therapeutics; Lilly
 
Madeleine Hewish
No Relationships to Disclose
 
Tom Roques
Research Funding - Merck; Merck; Merck; Merck
 
Fareeda Y. Coxon
No Relationships to Disclose
 
Carys Morgan
Travel, Accommodations, Expenses - Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications
 
Jonathan Wadsley
Honoraria - Eisai; Eisai; Eisai; Eisai; Genzyme; Genzyme; Genzyme; Genzyme
Speakers' Bureau - Eisai; Eisai; Eisai; Eisai; Genzyme; Genzyme; Genzyme; Genzyme
Research Funding - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Genzyme; Genzyme; Genzyme; Genzyme
Travel, Accommodations, Expenses - Celgene; Celgene; Celgene; Celgene; Genzyme; Genzyme; Genzyme; Genzyme; Imaging Equipment Limited; Imaging Equipment Limited; Imaging Equipment Limited; Imaging Equipment Limited; Ipsen; Ipsen; Ipsen; Ipsen
 
Tom Waddell
Honoraria - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; EUSA Pharma; EUSA Pharma; EUSA Pharma; EUSA Pharma; Ipsen; Ipsen; Ipsen; Ipsen; Pfizer; Pfizer; Pfizer; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Ipsen; Ipsen; Ipsen; Ipsen; Pfizer; Pfizer; Pfizer; Pfizer; Roche; Roche; Roche; Roche
Research Funding - Bristol-Myers Squibb (Inst); Ipsen (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; EUSA Pharma; EUSA Pharma; EUSA Pharma; EUSA Pharma; Ipsen
 
Naureen Starling
Honoraria - Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Pierre Fabre; Pierre Fabre; Pierre Fabre; Pierre Fabre; SERVIER
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; SERVIER; SERVIER; SERVIER; SERVIER
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Pfizer/EMD Serono (Inst); Pfizer/EMD Serono (Inst); Pfizer/EMD Serono (Inst); Pfizer/EMD Serono (Inst)
Travel, Accommodations, Expenses - MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology
 
Ian Chau
Honoraria - Lilly; Lilly; Lilly; Lilly
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Oncologie; Oncologie; Oncologie; Oncologie; Pierre Fabre; Pierre Fabre; Pierre Fabre; Pierre Fabre; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech
Research Funding - Janssen-Cilag (Inst); Janssen-Cilag (Inst); Janssen-Cilag (Inst); Janssen-Cilag (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono; MSD; MSD; MSD; MSD